NCT07329725

Brief Summary

This study aims to evaluate the impact of genetic drivers (somatic and inherited thrombophilias), acquired risk factors, and management strategies on survival and clinical outcomes in patients with VVT using a hybrid prospective-retrospective cohort design.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
101

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Dec 2025Dec 2026

Study Start

First participant enrolled

December 14, 2025

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

December 23, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 9, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 14, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 14, 2026

Last Updated

January 9, 2026

Status Verified

January 1, 2026

Enrollment Period

1 year

First QC Date

December 23, 2025

Last Update Submit

January 6, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patients diagnosed with visceral venous thrombosis

    To evaluate the impact of genetic drivers (somatic and inherited thrombophilias), acquired risk factors, and management strategies on survival and clinical outcomes in patients with VVT using a hybrid prospective-retrospective cohort design.

    The retrospective component will include eligible patients diagnosed within the preceding ten years, whereas the prospective component will enroll newly diagnosed patients and follow them for one year.

Secondary Outcomes (1)

  • Frequency and distribution

    The retrospective component will include eligible patients diagnosed within the preceding ten years, whereas the prospective component will enroll newly diagnosed patients and follow them for one year.

Study Arms (2)

Retrospective Cohort Analysis

Review of medical records to analyze demographic, clinical, and molecular data. Assessment of treatment regimens and outcomes, including thrombotic events, disease progression, and survival rates.

Other: Doppler ultrasonography

Prospective Cohort Analysis

Consecutive patients will be diagnosed with VVT from \[date of ethical approval\] forward, enrolled at diagnosis and followed prospectively with standardized baseline testing (including comprehensive genetic panel) and predefined follow-up visits.

Other: Doppler ultrasonography

Interventions

Radiological intervention Basic laboratory investigations, and Thrombophilia diagnosis

Also known as: Chest-X ray, Electrocardiogram (ECG), Echocardiography if indicated., CT angiography, MR venography, Doppler of the limbs, Basic laboratory investigations, Thrombophilia diagnosis
Prospective Cohort AnalysisRetrospective Cohort Analysis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with visceral venous thrombosis, including portal, mesenteric, splenic, renal and hepatic vein thrombosis in Department of Internal Medicine, Sohag University Hospital.

You may qualify if:

  • Adult patients (≥ 18 years) with radiologically confirmed visceral venous thrombosis.
  • Availability of complete clinical, laboratory, and imaging data at diagnosis.
  • Patients who consent to participate and provide blood samples for genetic testing.

You may not qualify if:

  • Isolated lower-limb deep-vein thrombosis or pulmonary embolism without visceral involvement.
  • Patients with incomplete records precluding outcome assessment.
  • Refusal or inability to provide informed consent
  • Patients lost to follow-up within the first three months of diagnosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, 82511, Egypt

Location

Related Publications (2)

  • Boccatonda A, Gentilini S, Zanata E, Simion C, Serra C, Simioni P, Piscaglia F, Campello E, Ageno W. Portal Vein Thrombosis: State-of-the-Art Review. J Clin Med. 2024 Mar 6;13(5):1517. doi: 10.3390/jcm13051517.

    PMID: 38592411BACKGROUND
  • Cohen O, Caiano LM, Tufano A, Ageno W. Cancer-Associated Splanchnic Vein Thrombosis. Semin Thromb Hemost. 2021 Nov;47(8):931-941. doi: 10.1055/s-0040-1722607. Epub 2021 Jun 11.

    PMID: 34116580BACKGROUND

MeSH Terms

Interventions

Ultrasonography, Doppler, TranscranialX-Rays

Intervention Hierarchy (Ancestors)

EchoencephalographyNeuroradiographyNeuroimagingDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisRadiographyUltrasonographyUltrasonography, DopplerDiagnostic Techniques, NeurologicalInvestigative TechniquesElectromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Study Officials

  • Mahmoud I Yousef, Associate Prof.

    Sohag University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 23, 2025

First Posted

January 9, 2026

Study Start

December 14, 2025

Primary Completion (Estimated)

December 14, 2026

Study Completion (Estimated)

December 14, 2026

Last Updated

January 9, 2026

Record last verified: 2026-01

Locations